Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants-Reference-Cited by-同舟云学术

Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants

Published:2021-06-22 Issue:12 Volume:60 Page:1591-1604
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Ganguly Samit^ORCID,Edginton Andrea N.,Gerhart Jacqueline G.^ORCID,Cohen-Wolkowiez Michael^ORCID,Greenberg Rachel G.,Gonzalez Daniel^ORCID,Benjamin Jr Daniel K.,Hornik Christoph,Zimmerman Kanecia,Kennel Phyllis,Beci Rose,Hornik Chi Dang,Kearns Gregory L.,Laughon Matthew,Paul Ian M.,Sullivan Janice,Wade Kelly,Delmore Paula,Taylor-Zapata Perdita,Lee June,Anand Ravinder,Sharma Gaurav,Simone Gina,Kaneshige Kim,Taylor Lawrence,Green Thomas,Kantak Anand,Ohlinger Judy,Horgan Mike,Boynton Susan,Eichenwald Eric C.,Jones Karen,Durand David J.,Asselin Jeanette,Arrieta Antonio,Shea Kathy,Wade Kelly,Morrison Tonia,Brozanski Beverly S.,Baker Robyn,Weitkamp Joern-Hendrik,Nannie Millie,Sanchez Pablo,Montanye Shirley,van den Anker John,Williams Elaine,Smith P. Brian,Cohen-Wolkowiez Michael^ORCID,Bidegain Margarita,Benjamin Jr Daniel K.,Grimes Sandy,MacKendrick William,Wolf Sue,Poindexter Brenda,Wilson Leslie Dawn,Castro Lisa M.,Harris Ann,Balaraman Venkataraman,Morse Robyn,Rasmussen Maynard,Arnell Kathy,Valencia Gloria,Higgerson Sara,Walsh Michele,Zadell Arlene,Roane Claire M.,Finer Neil,Capparelli Edmund V.,Rich Wade,Burchfield David,Miller Cindy,Sullivan Janice E.,Pierce Gwendolyn,Bhatt-Mehta Varsha,Dechert Ron,Ward Robert M.,Narus JoAnn,Bizzaro Mathew,Konstantino Monica,

Funder

Eunice Kennedy Shriver National Institute of Child Health and Human Development

National Institute of General Medical Sciences

American Foundation for Pharmaceutical Education

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-021-01046-6.pdf

Reference53 articles.

1. MERREM(R) IV (meropenem for injection), for intravenous use. 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050706s041lbl.pdf. Accessed 8 May 2020.

2. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis. 2008;47(Suppl. 1):S32-40.

3. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis. 1998;27:10–22.

4. Thyrum PT, Yeh C, Birmingham B, Lasseter K. Pharmacokinetics of meropenem in patients with liver disease. Clin Infect Dis. 1997;24(Suppl. 2):S184–90.

5. Burman LÅ, Nilsson-ehle I, Hutchison M, Haworth SJ, Norrby SR. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J Antimicrob Chemother. 1991;27:219–24.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does Two-Step Infusion Improve the Pharmacokinetics/Pharmacodynamics Target Attainment of Meropenem in Critically Ill Patients?;Journal of Pharmaceutical Sciences;2024-09

2. Physiologically-Based Pharmacokinetic Modeling and Dosing Optimization of Cefotaxime in Preterm and Term Neonates;Journal of Pharmaceutical Sciences;2024-08

3. Antibiotics, Analgesic Sedatives, and Antiseizure Medications Frequently Used in Critically Ill Neonates: A Narrative Review;Children;2024-07-18

4. Evaluation of pharmacokinetic pharmacodynamic target attainment of meropenem in pediatric patients;Pediatrics & Neonatology;2024-07

5. Use of population pharmacokinetic‐pharmacodynamic modelling to inform antimalarial dose optimization in infants;British Journal of Clinical Pharmacology;2024-06-10